Company Description
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair.
Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases.
Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-β, for the treatment of patients with idiopathic pulmonary fibrosis.
Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Craig Parker |
Contact Details
Address: 171 Oyster Point Boulevard, Suite 400 South San Francisco, California 94080 United States | |
| Phone | 650 489 9000 |
| Website | surrozen.com |
Stock Details
| Ticker Symbol | SRZN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1824893 |
| CUSIP Number | 86889P109 |
| ISIN Number | US86889P2083 |
| Employer ID | 30-1374889 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig C. Parker M.B.A. | Chief Executive Officer, President and Director |
| Charles Williams | Chief Operating Officer and Corporate Secretary |
| Dr. Yang Li Ph.D. | Executive Vice President of Research |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Roeland Nusse Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Calvin Kuo M.D., Ph.D. | Co-Founder and Member of Scientific Advisor |
| Andrew Maleki | Chief Financial Officer |
| Dr. Daniel L. Chao M.D., Ph.D. | Vice President and Head of Clinical Development |
| Michael Lauw M.S.W. | Senior Vice President of Development Operations |
| Esther Jhun | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2026 | SCHEDULE 13G | Filing |
| Apr 1, 2026 | ARS | Filing |
| Apr 1, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 1, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 30, 2026 | EFFECT | Notice of Effectiveness |
| Mar 30, 2026 | 424B5 | Filing |
| Mar 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 23, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 23, 2026 | 10-K | Annual Report |
| Mar 23, 2026 | 8-K | Current Report |